Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06233253
Other study ID # OSU-23136
Secondary ID NCI-2023-10496
Status Recruiting
Phase N/A
First received
Last updated
Start date September 29, 2023
Est. completion date December 31, 2024

Study information

Verified date January 2024
Source Ohio State University Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial tests how well an online mindfulness-based intervention (MBI) works to decrease anxiety in patients before a first-time screening colonoscopy. Elevated pre-procedural anxiety can affect patient outcomes including bowel preparation adherence and quality, the amount of sedation required, procedure time, patient satisfaction, cancellation or no-shows, and intention for future cancer screening. Mindfulness is a form of meditation that focuses on staying within the present moment to reduce anxiety. Previous research supports mindfulness practice among cancer survivors to decrease anxiety, fear of cancer re-occurrence, and to improve quality of life. Online MBIs have the potential to include targeted meditations and educational information designed to promote behavior change. This study may help researchers learn whether a mindfulness intervention works to decrease anxiety in patients before a first-time screening colonoscopy.


Description:

PRIMARY OBJECTIVE: I. To establish intervention feasibility and acceptability, and to collect preliminary efficacy data on a developed online mindfulness-based intervention (MBI) to reduce pre-procedural anxiety before a first-time screening colonoscopy compared to usual care. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients receive usual care prior to their scheduled screening colonoscopy. GROUP II: Patients receive an online mindfulness intervention including infographics and 5-minute meditations once daily (QD) for 5 days prior to their scheduled screening colonoscopy. After completion of study intervention, patients are followed up 1-2 days post-colonoscopy.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria: - Patients must be ages 45-75 - Patients must be at average risk for colorectal cancer (CRC) - Patients must have scheduled their first-time screening colonoscopy as an outpatient at Ohio State University (OSU) at least 14 days in advance - Patients must be able to speak and read English - Patients must have daily access to a working telephone, email address, and internet connection - Patients must provide consent Exclusion Criteria: - Previous colonoscopy - Colonoscopy for diagnostic purposes - Auditory or visual impairment that prevents internet use - Previous cancer diagnosis (other than skin cancer) - Previous diagnosis of a mental health disorder - Current mental health treatment - Family history of CRC - Personal history of inflammatory bowel disease (ulcerative colitis or Crohn's disease) - Confirmed or suspected hereditary CRC syndrome, such as familial adenomatous polyposis or Lynch syndrome

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Best Practice
Receive usual care
Medical Chart Review
Ancillary studies
Behavioral:
Online Mindfulness Meditation
Receive an online mindfulness intervention
Other:
Survey Administration
Ancillary studies

Locations

Country Name City State
United States Ohio State University Comprehensive Cancer Center Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retention rate (Feasibility) Feasibility will be assessed by the number of patients referred, number of participants recruited, and missing data from surveys and medical records. Feasibility will be achieved with a retention rate of 90% throughout the intervention. An independent samples t-test will be conducted to compare State-Trait Anxiety Inventory: State-Subscale (STAI-S) scores. Linear regression will be conducted to assess the difference when controlling for potential confounding variables of interest. Up to 4 weeks
Primary Satisfaction with the intervention (Acceptability) Acceptability will be assessed by the number of intervention materials accessed and time to complete study activities (infographics, meditations, and surveys) via embedded REDCap metrics. Participants within the MBI group will also report meditation satisfaction and state mindfulness immediately after each meditation in addition to intervention satisfaction during the follow-up survey. Will report an average satisfaction score with the intervention >= 6.0, measured using a 7-point Likert scale. An independent samples t-test will be conducted to compare STAI-S scores. Linear regression will be conducted to assess the difference when controlling for potential confounding variables of interest. At follow-up (1-2 days after the colonoscopy)
Secondary Colonoscopy nervousness Anxiety specific to the bowel prep and colonoscopy will be assessed using a visual analogue scale. Will be analyzed using t-test. At pre-colonoscopy assessment
Secondary Mindfulness Will measure the trait mindfulness using The Philadelphia Mindfulness Scale, a 20-item self-report with subscales of awareness and acceptance. Will be analyzed using t-test. At follow-up (1-2 days after the colonoscopy)
Secondary Mindfulness knowledge Will be assessed using a 5-item score about mindfulness. An independent samples t-test will be conducted to compare STAI-S scores. At follow up (1-2 days after the colonoscopy)
Secondary Colorectal screening knowledge Will be assessed using a 5-item score about colorectal (CRC) screening. Will be analyzed using t-test. At follow up (1-2 days after the colonoscopy)
Secondary Attitudes about CRC and CRC screening Will be self-reported and measured on a 5-point Likert scale. Will be analyzed using t-test. At follow up (1-2 days after the colonoscopy)
Secondary Bowel prep adherence Will be self-reported and measured on a 5-point Likert scale. Will be analyzed using chi-square test. At pre-colonoscopy assessment
Secondary Bowel prep difficulty Will be self-reported and measured on a 5-point Likert scale. Will be analyzed using t-test. At pre-colonoscopy assessment
Secondary Bowel prep quality Will be measured using the Boston Bowel Preparation Scale or 5-point Likert scale and medical chart review. Will be analyzed using t-test. Up to 4 weeks
Secondary Cancellation/no-show Will be measured by attendance. Will be analyzed using chi-square test. At pre-colonoscopy assessment
Secondary Heart rate Will be measured in beats per minute using medical chart review. Will be analyzed using t-test. Up to 4 weeks
Secondary Blood pressure Will be measured in millimeter of mercury using chart review at time of check-in (the first recorded) to the endoscopy suite holding area. Will be analyzed using t-test. Up to 4 weeks
Secondary Sedative dose Will be measured in milligrams using chart review. Will be analyzed using t-test. Up to 4 weeks
Secondary Procedural time Will be measured in minutes using medical chart review. Will be analyzed using t-test. Up to 4 weeks
Secondary Cecal intubation time Will be measured in minutes using medical chart review. Will be analyzed using t-test. At post-colonoscopy
Secondary Endoscopy suite time Will be measured in minutes using medical chart review. Will be analyzed using t-test. Up to 4 weeks
Secondary Procedure satisfaction Will be self-reported and measured on a 5-point Likert scale. Will be analyzed using t-test. At follow up (1-2 days after the colonoscopy)
Secondary Intent for future CRC screening Will be self-reported and measured on a 5-point Likert scale. Will be analyzed using t-test. At follow up (1-2 days after the colonoscopy)
See also
  Status Clinical Trial Phase
Completed NCT04444232 - Cancer Communication Within Hispanic Social Networks N/A
Recruiting NCT05799820 - QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC Phase 2
Recruiting NCT04666727 - Role of Diet on the Microbiome of the Digestive System
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Recruiting NCT02376452 - Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients Phase 2
Completed NCT02254486 - Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults Phase 3
Completed NCT01486251 - Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer N/A
Terminated NCT01233544 - Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases Phase 3
Recruiting NCT02073500 - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Completed NCT00704600 - Nelfinavir, a Phase I/Phase II Rectal Cancer Study Phase 1/Phase 2
Completed NCT00485316 - Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma Phase 3
Recruiting NCT04430738 - Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers Phase 1/Phase 2
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT05022511 - Three Birds With One Stone N/A
Completed NCT04607291 - Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening Phase 1
Not yet recruiting NCT03969784 - Microparticles in Peritoneal Carcinomatosis of Colorectal Origin N/A
Not yet recruiting NCT05630794 - Testing ONC201 to Prevent Colorectal Cancer Phase 1
Terminated NCT05291988 - A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial N/A
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03142516 - FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status Phase 2

External Links